Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.69 |
| ▸ | BCR | P11274 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 15/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 13/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.55 |
| ▸ | TNNI3K | Q59H18 | 11/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239038 | 0.86 | AURKA (0.70) | ABL1BCRAURKAKDM4EMAPT | |
| SCHEMBL4239383 | 0.84 | KDR (0.57) | ABL1BCRKDRBRAFMAPK14 | |
| SCHEMBL12262244 | 0.81 | MAP2K7 (0.66) | KDRBRAFMAPK14TNNI3K | |
| SCHEMBL13777941 | 0.81 | KDR (0.81) | KDRAURKABRAF | |
| SCHEMBL12262247 | 0.77 | KDR (0.51) | ABL1BCRKDRBRAFMAPK14 | |
| SCHEMBL4234986 | 0.76 | AURKA (0.55) | ABL1BCRKDRAURKATNNI3K | |
| SCHEMBL4244096 | 0.74 | L3MBTL1 (0.57) | KDRBRAFMAPK14TNNI3KMAPT | |
| SCHEMBL4235267 | 0.74 | AURKA (0.55) | ABL1BCRKDRAURKATNNI3K | |
| SCHEMBL8199722 | 0.74 | MAPT (0.54) | KDRBRAFMAPK14TNNI3KMAPT | |
| SCHEMBL3175643 | 0.73 | KDR (0.77) | KDRBRAFMAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | claimed |
| EP-1943233-A2 | COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2008-07-16 | — | — | EP | claimed |
| WO-2007056151-A2 | PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | claimed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ERBB2, BMX, ERBB3 | ABL1 75/4885BCR 313/4885KDR 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.